• Alnylam Pharmaceuticals average ebitda margin for 2023 was -36.25%, a 47.88% decline from 2022.
• Alnylam Pharmaceuticals average ebitda margin for 2022 was -69.55%, a 26.48% decline from 2021.
• Alnylam Pharmaceuticals average ebitda margin for 2021 was -94.6%, a 59.44% decline from 2020.

Ebitda margin can be defined as earnings before interest, taxes, depreciation and amortization as a portion of total revenue.